Incyclix Bio
  • About Us
    • Mission/Vision
    • Founding Story
    • Leadership
    • Board of Directors
    • Investors
  • Science
    • Approach
    • CDK2 Program
    • Clinical Trials
    • Publications
  • News
    • Press Releases
    • Publications
  • Join Us
  • Contact Us

Recent News


February 28, 2023

Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer

Read More >

March 31, 2022

Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital

Read More >

August 5, 2020

ARC Therapeutics Launches to Develop Novel CDK Inhibitors for the Treatment of Advanced and Resistant Cancers

Read More >

Incyclix Bio

600 Park Offices Dr., Suite 355
Research Triangle Park, NC 27709

(919) 328-0003
info@incyclixbio.com

LinkedIn
Twitter

© 2023 Incyclix Bio, Inc. All Rights Reserved.